stockrow
Friday 6 November 2026
Export RLYB’s income statement to Excel — free account
Rallybio Corporation
RLYB Healthcare Biotechnology
Rallybio Corporation’s revenue for fiscal 2025 (year ended December 2025) was $858,000.00, up 34.9% from fiscal 2024.
- Revenue
- 0.00%
- EPS
- −116.6%
- Free cash flow
- +65.3%
Quarter to September 2026, against a year earlier
15.74
0.16
−1.01%
Follow RLYB
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Sep ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | 1 | 1 | 1 | +34.9% | 1 | 1 | — | (7.6%) | |
| Gross margin, % | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | — | 100.00 | 100.00 | 100.00 | +100.0 pt | ||||||
| EBT | — | — | — | (17) | (25) | (46) | (66) | (73) | (56) | (8) | 28 | (12.0%) | ||||||
| EBT margin, % | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (8,732.08) | (944.52) | 0.00 | (944.5) pt | ||||||
| Net income | — | 0 | — | (18) | (26) | (47) | (67) | (75) | (58) | (9) | 27 | n/m | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.12 | 0.15 | 0.00 | n/m | |||||
| Earnings | — | — | — | (0.55) | (12.17) | (14.72) | (16.72) | (14.72) | (10.64) | (1.59) | 4.70 | +19.4% | ||||||
| Cash flow | — | — | — | (0.47) | (10.14) | (14.27) | (14.40) | (11.92) | (9.05) | (5.30) | 5.42 | +49.8% | ||||||
| Capex | — | — | — | 0.00 | (0.06) | (0.10) | (0.01) | 0.00 | 0.00 | 0.00 | 0.00 | n/m | ||||||
| Free cash flow | — | — | — | (0.47) | (10.20) | (14.38) | (14.42) | (11.92) | (9.05) | (5.30) | 5.42 | +49.8% | ||||||
| Book value | — | — | — | 0.52 | 62.57 | 55.05 | 42.57 | 21.00 | 11.33 | 10.29 | 16.15 | +64.2% | ||||||
| Shares, m | — | — | — | 32 | 2 | 3 | 4 | 5 | 5 | 6 | 6 | (25.2%) | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | 0.00 | 0.00 | 3.35 | 0.0 | |||||
| P/S | — | — | — | — | — | — | — | — | 0.00 | 36.02 | 104.84 | 18.0 | ||||||
| P/B | — | — | — | — | — | — | — | — | 0.68 | 0.53 | 0.97 | 0.6 | ||||||
| EV/Sales | — | — | — | — | — | — | — | — | 0.00 | (27.77) | (0.86) | (13.9) | ||||||
| EV/FCF | — | — | — | — | — | — | — | — | 0.48 | 0.80 | (0.02) | 0.6 | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | (15) | (22) | (46) | (57) | (60) | (49) | (30) | 31 | +12.1% | |||||
| Capex | — | — | — | 0 | 0 | 0 | 0 | 0 | — | — | 0 | (49.7%) | ||||||
| Free cash flow | — | — | — | (15) | (22) | (46) | (57) | (60) | (49) | (30) | 31 | +12.1% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | — | — | — | 17 | 135 | 174 | 169 | 106 | 62 | 57 | 91 | +22.2% | |||||
| Net debt | — | — | — | (19) | (140) | (175) | (169) | (110) | (66) | (55) | (91) | +18.8% | ||||||
| Shareholders’ equity | — | — | — | 17 | 136 | 176 | 169 | 106 | 62 | 58 | 92 | +22.8% | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | — | — | — | (162.57) | (32.36) | (29.02) | (36.76) | (50.37) | (62.89) | (13.77) | 32.85 | +148.8 pt | |||||
| ROIC | — | — | — | 0.00 | 0.00 | (10,645.52) | (13,135.45) | 0.00 | 0.00 | (641.77) | (944.36) | (641.8) pt | ||||||
| ROE | — | — | — | 0.00 | (45.71) | (30.17) | (38.65) | (54.13) | (68.85) | (15.01) | 34.52 | (15.0) pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | — | — | 28 | 35 | 41 | 43 | 25 | 14 | — | (12.9%) | |||||
| Revenue/emp, $m | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.03 | 0.06 | — | n/m | ||||||
Negative figures in brackets.
estimates
Fiscal years to Dec 2025 · latest quarter Mar 2026 · fundamentals updated 2 Nov 2026
Rallybio Corporation vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| EQ Equillium, Inc. | $88.8M | — (loss-making) | — (loss-making) | −52.32% (below 0%: shrinking) | n/m | −38.67% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| GNLX Genelux Corporation | $88.7M | — (loss-making) | — (loss-making) | — | n/m | −11.18% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| TNXP Tonix Pharmaceuticals Holding Corp. | $87.6M | — (loss-making) | — (loss-making) | +577.88% (above 0%: growing) | n/m | −178.84% (below 0%: shrinking) | 94.81% | (314.05%) | Compare |
| NRXS Neuraxis, Inc. | $86.2M | — (loss-making) | — (loss-making) | +115.71% (above 0%: growing) | n/m | +29.76% (above 0%: growing) | 85.87% | (110.16%) | Compare |
| RLYB Rallybio Corporation | $85.6M | 3.3× | — (loss-making) | 0.00% | n/m | +65.25% (above 0%: growing) | 100.00% | 0.00% | |
| CLLS Cellectis S.A. | $84.6M | — (loss-making) | — | −62.05% (below 0%: shrinking) | n/m | −36.95% (below 0%: shrinking) | 100.00% | (340.69%) | Compare |
| TNYA Tenaya Therapeutics, Inc. | $84.3M | — (loss-making) | — | — | n/m | −13.18% (below 0%: shrinking) | 100.00% | (1,153.33%) | Compare |
| ATRA Atara Biotherapeutics, Inc. | $84.0M | — (loss-making) | — (loss-making) | −96.42% (below 0%: shrinking) | n/m | +52.10% (above 0%: growing) | 69.68% | (749.21%) | Compare |
| TLSA Tiziana Life Sciences Ltd | $81.9M | — (loss-making) | — | — | −258.11% (below 0%: shrinking) | +18.03% (above 0%: growing) | 0.00% | — | Compare |
| Median of peers | $85.4M | — | — | −52.32% | — | −12.18% | 97.41% | (314.05%) |
Pay and ownership Proxy statement filed 2 January 2026
Ownership
Directors and executive officers, together
10.30%
Entities affiliated with Viking Global Investors LP
9.90%
Entities affiliated with Johnson & Johnson
8.60%
Entities affiliated with
8.60%
Ronald Hunt, M.B.A.
8.20%
Entities affiliated with New Leaf Venture Partners
7.80%
Entities affiliated with TPG Inc.
7.20%
Robert Hopfner, R.Ph., Ph.D., M.B.A.
6.00%
Entities affiliated with Pivotal bioVenture Partners
5.70%
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more.
Read the proxy statement